This website is intended for individuals living in the United States.

About LN and pMN

About lupus

Lupus is an autoimmune disease that can cause pain, fatigue, and inflammation throughout the body. In about half of adults living with lupus, it also damages the kidneys,1 leading to lupus nephritis (LN), which can worsen over time and may cause kidney failure.2 Researchers are exploring new therapies that may better protect kidney function.

About primary membranous nephropathy

Primary membranous nephropathy (pMN) is a rare autoimmune kidney disease where antibodies attack the kidney’s filtering units. This can cause protein in the urine, swelling, weight gain from fluid buildup, and high blood pressure. Without effective treatment, pMN may worsen over time and lead to kidney failure. Researchers are exploring new therapies that may better protect kidney function.3

  1. niddk.nih.gov/health-information/kidney-disease/lupus-nephritis↵
  2. kidney.org/kidney-topics/lupus-nephritis↵
  3. my.clevelandclinic.org/health/diseases/21154-membranous-nephropathy↵

About the Ntrust-1 study

In this study, an investigational cell therapy called NKX019 will be tested in adults living with lupus nephritis (LN) and primary membranous nephropathy (pMN). NKX019 has been tested in research laboratories and cleared by applicable health and regulatory authorities for evaluation in people. Researchers are still learning about the safety and effectiveness of NKX019.

Currently, steroids are commonly prescribed for these conditions to reduce symptoms that arise when the body’s immune system mistakenly attacks healthy tissue and vital organs. However, steroids do not treat the actual cause of the condition, and symptoms often return.

The goal of this study is to test the investigational cell therapy’s ability to safely target the underlying cause of these diseases, rather than only addressing the symptoms after they appear.

The purpose of this study is to:

  • Determine if NKX019 is safe to use and how well it is tolerated in the body
  • Determine if NKX019 can improve kidney function
  • See if other medications like steroids can be stopped because LN or pMN is controlled
  • See how the body processes NKX019 by measuring the NKX019 levels in the blood

Do I qualify?

Supporting study participants

Taking part in a clinical study can present challenges, such as travel and other costs. In the Ntrust-1 study, costs for study-related travel, lodging, childcare, and meals may be covered when you and your care partner go to the study clinic for required visits.

Compensation for you and your care partner may also be available to offset other potential barriers.

Who can participate

You may be eligible to participate in this study if you:

  • Are 18 to 70 years old
  • Have been diagnosed with lupus nephritis (LN) or primary membranous nephropathy (pMN)
  • Have previously received at least 2 therapies for kidney issues
  • Do NOT currently require renal (kidney) dialysis

There are additional requirements, which the study team will review with you during your first visit to the clinic.

Prescreener entry

Step 1 of 4

Welcome to the Ntrust-1 study prescreener. In this study, an investigational cell therapy called NKX019 will be tested in adults living with lupus nephritis (LN) or primary membranous nephropathy (pMN).

Based on your answers in this prescreener, you may be contacted by the study team for further screening or referred to a study site. If you answer these questions and are contacted for further screening or referred to a study site, that does not mean you have to join the study.

First, we need your consent to process and share any information you provide as part of this prescreener.

The information collected in this prescreener is personal. Protecting this information is a top priority for us. This is why we have a detailed privacy policy that includes making certain you understand how we will handle the information you provide here. Your participation in this prescreener process is voluntary, and you can withdraw your consent at any time as described in the privacy policy. The only consequence of withdrawing your consent will be that you will not be able to continue participating in the prescreener process. Please note that our role in the study is limited to screening potentially eligible candidates only.

Are you located in the United States?

e.g., 12345

Are you between 18 and 70 years of age?

MM/YYYY

This website uses Secure Socket Layer technology and encryption methods to protect personal health information. If you’d like to know more about this, read the privacy policy.

What is NKX019?

NKX019 is an investigational cell therapy being studied for lupus nephritis (LN) and primary membranous nephropathy (pMN). It is designed to target and eliminate the cells that may trigger harmful antibodies, which attack the body’s own tissues in these conditions. Academic studies of a small number of autoimmune patients treated with other cell therapy products have indicated that if these cells can be eliminated, the harmful antibodies that attack the body’s own tissues in LN and pMN may also be eliminated. This could potentially slow or stop progression of the disease.

NKX019 is made from white blood cells called natural killer (NK) cells. NK cells are the immune system’s first responders and possess a unique, natural ability to target and kill disease-causing cells. NK cells are a normal part of the immune system and are present in everyone. The NK cells used in NKX019 are collected from healthy donors and then processed for use in NK cell therapy.

What tests and assessments are required?

Your Ntrust-1 study doctor and team will explain these to you and answer any questions you may have about them. You may also need to have some tests or assessments not shown here.

Physical exam/vital signs

Heart tests (electrocardiograms and echocardiograms)

Kidney biopsy (if not done in the past 6 months)

Discussions with your study doctor and team*

Pregnancy test (if applicable)

Collection of blood samples

Collection of urine samples

LN or pMN assessments

Intravenous infusions

Surveys

*Discussions include topics such as changes in your health, side effects, and other medications you may take.

What will be expected of me during the study?

Studies like Ntrust-1 rely on the cooperation of volunteer participants. While you are in this study, you will need to:

  • Follow instructions from your study doctor and team
  • Come to your study visits
  • Complete the required tests and assessments
  • Receive study infusions as scheduled
  • Stay after each infusion of NKX019 for at least 24 hours to be watched for side effects
  • Complete home monitoring activities
  • Report any changes in your health

You will have the full support of your study doctor and team. They will answer any questions you may have about what is expected of you. The study may also include additional requirements and restrictions as needed for your safety.

Frequently asked questions (FAQs)

  • Clinical studies, also called clinical trials, help determine if investigational medications are safe to use and work to improve the health of people. Before any investigational product can be approved and made available to the public, it must go through several phases of clinical research and governmental review.

  • People participate in clinical studies for a variety of reasons. Some participate because they want the chance to receive an investigational therapy being evaluated as a potential treatment. Others might want to learn more about their disease or health condition. They may want to play a more active role in their healthcare. The hope that they might help others living with the same disease in the future can motivate people as well. Each person can have their own reasons based on their unique health journey.

  • Studies follow specific standards and are closely regulated to help protect the participants. Studies are reviewed by independent groups called institutional review boards (IRBs) or ethics committees (ECs) before they can begin. The role of these groups is to ensure that the rights, safety, and well-being of study participants will be protected. Each study also includes strict safety measures and follows a written plan called a protocol. The protocol is designed to make sure study activities will be completed correctly and safely.

  • To make an educated and informed decision about whether study participation is right for you, you will be provided an informed consent form. This document explains the study purpose, tests and assessments, and potential benefits and risks. You will need to read the consent form carefully. Your Ntrust-1 study team will review it with you and answer any questions you may have. You can also talk with your healthcare providers about the study.

  • Each clinical study includes people who meet specific requirements. Some examples are age, diagnosis, and prior treatments. If you sign the informed consent form, your Ntrust-1 study team will review your medical history and conduct tests to learn more about your overall health and your lupus nephritis (LN) or primary membranous nephropathy (pMN). Your study doctor will review the results to determine if you meet the eligibility criteria.

    If you are interested in joining the Ntrust-1 study, you can start by answering a few questions in the study prescreener. Answering these questions does not obligate you to join the study.

    Do I qualify?

  • Your Ntrust-1 study doctor and team will provide study-related care. This will include study infusions, tests, and assessments. The study doctor and team have expertise in caring for people living with lupus nephritis (LN) or primary membranous nephropathy (pMN). They understand the daily challenges of this disease. You will continue to receive healthcare not related to the study from providers of your choosing.

  • You can visit any healthcare provider to meet your needs while you are in this study. You will need to let your study team know if you will be going to another provider and if any medications are prescribed, as some medications may not be allowed while you are in the study. You should also let other providers you visit know that you are in a clinical study.

  • You can ask questions at any point during the study. If you are ever unsure about what you need to do or what will happen, you can ask your study doctor and team. They will want to make sure you understand all study activities, including those you will need to complete at home. It is also important that you feel comfortable with the tests and assessments that will be done.

  • Study infusions, tests, and assessments will be provided at no cost to you. Costs for study-related travel, lodging, childcare, and meals for you and your care partner may be covered when you go to the study clinic for required visits. Compensation for you and your care partner may also be available to offset other potential burdens. You can ask your Ntrust-1 study team about all the support that may be available.

  • Before you decide if you want to join the Ntrust-1 study, you may want to talk with your family members or other care partners about the study. Together, you can decide if participating in this study may be right for you. If you choose to join the study, family members and other care partners can provide support in many ways. For example, they can bring you to visits, ask questions, and take notes. They can also help you keep track of your visits, prepare for visits, and complete study activities at home as needed.

  • There is no promise of direct medical benefit to you if you join this study. NKX019 is an investigational cell therapy. The safety of this therapy, and how effective it is, have not been established. The visits with your study team may give you more insight into your overall health and your lupus nephritis (LN) or primary membranous nephropathy (pMN). Additionally, what researchers learn about LN, pMN, and NKX019 may help people living with this disease in the future.

  • As with any clinical study, participating in the Ntrust-1 study comes with potential risks and side effects. The informed consent form that you will be given before you decide if you want to join this study describes the known risks and side effects. The study doctor and team will review these with you and answer your questions. They will watch you closely for signs of any side effects and address them as needed. It is important to know that there may also be risks and side effects that are not yet known.

  • Participating in this study is voluntary. If you choose to participate for the full duration of the study, it will help researchers learn more about NKX019 and long-term effects that it may have on lupus nephritis (LN) and primary membranous nephropathy (pMN). However, you can stop at any time and for any reason. There will be no negative impact on the medical care you receive outside the study.

  • Nkarta, Inc., is a biotechnology company based in South San Francisco advancing the development of natural killer (NK) cell therapies for autoimmune diseases. The NK cells are collected from healthy donors and engineered to target and eliminate other cells that can lead to autoimmune disease.

Find a study site near you

Use the map below to find a nearby study site and see where the Ntrust-1 study is enrolling.